Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

growth hormone disorder

- PMLiVE

Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

A rapid round up of pharma, biotech and healthcare news

- PMLiVE

Biotech: it’s a people business

Nancy Hunter is the Marketing Director at a cutting-edge pharmaceutical company. Here she explains how a sharp focus on patients’ needs is driving a new operating model for marketing first-in-class...

Blue Latitude Health

Is the pharma business model ready for precision medicine?

Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Blue Latitude Health

- PMLiVE

P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit

Will also access Merck’s big-selling Neurobion and the Nasivin nasal decongestant range

Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Blue Latitude Health

- PMLiVE

Commercial innovation in biotech organisations

Blue Latitude Health speaks to Salma Jutt Vice President of US Marketing and Head of Commercial Innovation at a biotech specialising in treating weight loss and obesity.

Blue Latitude Health

- PMLiVE

Merck KGaA inks deal for Medisafe adherence app

The digital programme will be initially rolled out in Brazil, Russia and Mexico

Sanofi ponders which African health tech start-ups to bring to Paris

It's on the look out for those working in non-communicable diseases, telemedicine and HCP education

Implementing eHealth innovation

How Merck’s PMEA-winning progress in new technology  is improving outcomes for young patients

- PMLiVE

Merck and Pfizer set to win NICE backing for Bavencio

The PD-L1 inhibitor is being assessed for the treatment of mMCC patients

- PMLiVE

Merck/Pfizer’s cancer immunotherapy latecomer hits a snag

Bavencio fails a key lung cancer trial

- PMLiVE

Merck forges closer ties with Cancer Research UK

Will partake in three research projects covering hit discovery to preclinical candidate selection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links